<DOC>
	<DOC>NCT00242762</DOC>
	<brief_summary>The primary objective of the study is to evaluate the activity of the combination ZD1839, docetaxel and cisplatin in subjects with recurrent and/or metastatic head and neck cancer by estimating the objective response rate (complete response [CR] and partial response [PR]) at study closure.</brief_summary>
	<brief_title>ZD1839 (IRESSAâ„¢) in Combination With Docetaxel &amp; Cisplatin in Subjects With Metastatic Head &amp; Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1. Male or female, aged 18 and 70 years, inclusive 2. Histologically or cytologicallyconfirmed recurrent and/or metastatic SCCHN 3. Primary tumour site of oral cavity, oropharynx, hypopharynx or larynx 4. At least one unidimensionally measurable lesion according to the RECIST 5. World Health Organisation (WHO) performance status (PS) of 0 or 1 6. No previous chemotherapy for recurrent or metastatic disease 7. Before subject registration a quality of life questionnaire should be completed 1. Previous chemotherapy for recurrent or metastatic disease 2. Less than 6 months since prior induction or adjuvant platinum and/or taxanes chemotherapy 3. Known severe hypersensitivity to ZD1839 or any of the excipients of this product 4. Known, severe hypersensitivity to docetaxel or cisplatin or any of the excipients of these products, or to other drugs formulated with polysorbate 80 5. Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ 6. Any unresolved chronic toxicity greater than common toxicity criteria (CTC) grade 2 from previous anticancer therapy (except alopecia) 7. Absolute neutrophil count (ANC) less than 1.5 x109/litre (L), platelets less than 100 x 109/L or haemoglobin less than 10 g/dl 8. Serum bilirubin greater than the upper limit of the reference range (ULRR) 9. Serum creatinine greater than 1.5 mg/dl despite adequate rehydration 10. Creatinine clearance less than 60 ml/min assessed in over a 24 hour urine collection 11. As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) 12. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 1.5 times the ULRR or alkaline phosphatase (ALP) greater than 2.5 times the ULRR 13. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study 14. Pregnancy or breast feeding (women of childbearing potential) 15. Concomitant use of phenytoin, carbamazepine, rifampicin, or barbiturates, or St John's Wort 16. Treatment with a nonapproved or investigational drug within 30 days before Day 1 of study treatment 17. Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Head and Neck Neoplasms</keyword>
	<keyword>Cancer of Head and Neck</keyword>
	<keyword>Head and Neck Cancer</keyword>
	<keyword>Head Cancer</keyword>
	<keyword>Neck Cancer</keyword>
</DOC>